reviewNature ImmunologyOct 14, 2019Closed access

Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

LPLawrence P. AndrewsHYHiroshi YanoDADario A.A. Vignali

University of Pittsburgh · UPMC Hillman Cancer Center

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

532
total citations
FWCI
26.45
Percentile
100%
References
110
Citations per year

Authors

3

Topics & keywords

Topics
Keywords
  • TIGIT
  • Immunotherapy
  • Cancer immunotherapy
  • CTLA-4
  • PD-L1
  • Blockade
  • Immune checkpoint
  • Cancer
No related works found for this paper.

Funding